MedPath

Meloxicam

Generic Name
Meloxicam
Brand Names
Anjeso, Mobic, Qmiiz, Vivlodex
Drug Type
Small Molecule
Chemical Formula
C14H13N3O4S2
CAS Number
71125-38-7
Unique Ingredient Identifier
VG2QF83CGL
Background

Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis. With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is available in oral, transdermal, and intravenous formulations. It is a preferential COX-2 inhibitor, purportedly reducing the risk of adverse gastrointestinal tract effects, however, this is a topic of controversy.

Indication

Meloxicam is indicated for the symptomatic treatment of arthritis and osteoarthritis. In addition, it is indicated for the pauciarticular and polyarticular course of Juvenile Rheumatoid Arthritis (JRA) in patients aged 2 years old or above. Off-label uses include the treatment of dental or post-surgical pain. In addition to the above, meloxicam has also been studied in the treatment of neuropathic pain.

Meloxicam, in combination with bupivacaine, is indicated for postsurgical analgesia in adult patients for up to 72 hours following foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures.

Associated Conditions
Dental Pain, Neuropathic Pain, Osteoarthritis (OA), Pain, Inflammatory, Pauciarticular juvenile rheumatoid arthritis, Polyarticular juvenile rheumatoid arthritis, chronic or unspecified, Postoperative pain, Rheumatoid Arthritis

Non-Steroidal Anti-inflammatory Drugs in Axial Spondyloarthritis

Phase 4
Terminated
Conditions
Ankylosing Spondylitis
Axial Spondyloarthritis
Interventions
First Posted Date
2018-03-22
Last Posted Date
2020-09-22
Lead Sponsor
Columbia University
Target Recruit Count
9
Registration Number
NCT03473665
Locations
🇺🇸

Columbia University Irving Medical Center, New York, New York, United States

Evaluation of Preoperative N1539 in Total Knee Arthroplasty

Phase 3
Completed
Conditions
Pain, Postoperative
Interventions
Drug: Placebo
First Posted Date
2018-02-15
Last Posted Date
2023-05-25
Lead Sponsor
Baudax Bio
Target Recruit Count
194
Registration Number
NCT03434275
Locations
🇺🇸

Research Center, Vero Beach, Florida, United States

Evaluation of Preoperative N1539 in Colorectal Surgery

Phase 3
Completed
Conditions
Pain, Postoperative
Interventions
Drug: Placebo
First Posted Date
2017-10-27
Last Posted Date
2023-06-18
Lead Sponsor
Baudax Bio
Target Recruit Count
57
Registration Number
NCT03323385
Locations
🇺🇸

Research Center, Philadelphia, Pennsylvania, United States

Lidocaine-prilocaine Cream Versus Rectal Meloxicam on Relief of Post-episiotomy Pain

Phase 3
Completed
Conditions
Postpartum
Interventions
Drug: lidocaine-prilocaine cream
First Posted Date
2017-05-09
Last Posted Date
2019-08-19
Lead Sponsor
Assiut University
Target Recruit Count
190
Registration Number
NCT03146000
Locations
🇪🇬

Assiut Faculty of Medicine, Assiut, Egypt

Evaluation of N1539 Following Major Surgery

Phase 3
Completed
Conditions
Pain, Post-operative
Interventions
Drug: Intravenous Placebo
First Posted Date
2016-03-28
Last Posted Date
2023-06-22
Lead Sponsor
Baudax Bio
Target Recruit Count
722
Registration Number
NCT02720692

Treatment of Recent Onset Low Back Pain With Periradicular Injections of Meloxicam

Phase 3
Completed
Conditions
Low Back Pain
Interventions
Other: saline
First Posted Date
2016-03-11
Last Posted Date
2023-05-12
Lead Sponsor
Istituto Ortopedico Rizzoli
Target Recruit Count
80
Registration Number
NCT02706054
Locations
🇮🇹

Istituto ortopedico Rizzoli, Bologna, Italy

Evaluation of N1539 Following Abdominoplasty Surgery

Phase 3
Completed
Conditions
Pain, Post-operative
Interventions
Drug: Intravenous Placebo
First Posted Date
2016-02-09
Last Posted Date
2018-02-14
Lead Sponsor
Baudax Bio
Target Recruit Count
219
Registration Number
NCT02678286
Locations
🇺🇸

Endeavor Clinical Trials, San Antonio, Texas, United States

🇺🇸

Lotus Clinical Research, LLC, Pasadena, California, United States

🇺🇸

Research Concepts, Bellaire, Texas, United States

and more 1 locations

Evaluation of N1539 Following Bunionectomy Surgery

Phase 3
Completed
Conditions
Pain, Post-operative
Interventions
Drug: Intravenous Placebo
First Posted Date
2016-02-05
Last Posted Date
2017-11-17
Lead Sponsor
Baudax Bio
Target Recruit Count
201
Registration Number
NCT02675907
Locations
🇺🇸

Trovare Clinical Research, Bakersfield, California, United States

🇺🇸

Lotus Clinical Research, Pasadena, California, United States

🇺🇸

Chesapeake Research Group, Pasadena, Maryland, United States

and more 1 locations

Placebo-Controlled Evaluation of N1539 Following Bunionectomy Surgery

Phase 2
Completed
Conditions
Pain, Post-operative
Interventions
Drug: Intravenous Placebo
First Posted Date
2015-09-03
Last Posted Date
2017-06-14
Lead Sponsor
Baudax Bio
Target Recruit Count
59
Registration Number
NCT02540265
Locations
🇺🇸

Chesapeake Research Group, LLC, Pasadena, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath